Analyst Price Targets — ZURA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 10:49 am | Yatin Suneja | Guggenheim | $20.00 | $5.56 | TheFly | Zura Bio price target raised to $20 from $15 at Guggenheim |
| February 9, 2026 11:32 am | — | Wedbush | $15.00 | $6.01 | TheFly | Zura Bio initiated with an Outperform at Wedbush |
| April 3, 2025 10:12 am | Mitchell Kapoor | H.C. Wainwright | $3.00 | $1.09 | TheFly | Zura Bio price target lowered to $3 from $5 at H.C. Wainwright |
| November 8, 2024 6:47 pm | Yatin Suneja | Guggenheim | $15.00 | $4.58 | StreetInsider | Guggenheim Reiterates Buy Rating on Zura Bio Ltd. (ZURA) |
| September 5, 2024 6:09 am | Mitchell Kapoor | H.C. Wainwright | $5.00 | $3.95 | TheFly | Zura Bio initiated with a Neutral at H.C. Wainwright |
Latest News for ZURA
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: Cantor Global Healthcare…
Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Soligenix and Zura Bio's
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000…
Zura Bio Limited (Nasdaq: ZURA) (âZuraâ), a clinicalâstage biotechnology company developing novel and differentiated medicines to meaningfully improve the
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “The second quarter was…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZURA.
U.S. House Trading
No House trades found for ZURA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.